Inositol in Pregnancy and Breastfeeding: What the Evidence Supports

Is Myo-Inositol Safe to Take During Pregnancy?

Seven randomized trials covering 1,319 pregnant women have tested myo-inositol supplementation in pregnancy, and a 2023 Cochrane review of that pooled evidence found it may reduce gestational diabetes by roughly 47% (risk ratio 0.53, 95% CI 0.31–0.90) without turning up a clear signal of harm to mother or baby — but the review’s own authors rate every one of those conclusions low-to-very-low certainty, and six of the seven trials were run in Italy, one in Ireland, which limits how confidently the finding generalizes elsewhere. None of these trials recruited participants by a PCOS diagnosis; they enrolled women by pre-pregnancy weight category (obese, overweight) or by an elevated fasting glucose reading, which overlaps heavily with PCOS but is not the same as a PCOS-specific trial. The mechanism — inositol acting on insulin sensitivity — is the same reason it was tested in PCOS outside of pregnancy, so the evidence is relevant to a pregnant reader with PCOS, but it should not be read as inositol having been proven in PCOS pregnancies specifically.

What Did the Gestational Diabetes Prevention Trials Actually Find?

In 220 obese pregnant women randomized from 12–13 weeks of gestation, myo-inositol (2 g plus 200 mcg folic acid, twice daily — 4 g of myo-inositol total per day) cut the gestational diabetes rate to 14.0%, against 33.6% on placebo (P = .001, odds ratio 0.34), alongside a significantly greater improvement in insulin resistance (HOMA-IR change −1.0 versus 0.1, P = .048). A separate trial in 220 overweight — not obese — pregnant women, run by an overlapping research group using the identical regimen, found gestational diabetes in 11.6% of the myo-inositol group against 27.4% on placebo (p = .004), a 67% relative risk reduction. A smaller pilot trial in 75 women selected specifically for elevated early-pregnancy fasting glucose found an even larger relative effect — gestational diabetes risk ratio of 0.127 in the myo-inositol group — though the published abstract does not state the exact dose used, unlike the two larger trials above.

Does Myo-Inositol Affect the Baby, or the Delivery Itself?

Preterm birth occurred less often in the pooled trial data — a 35% relative reduction (risk ratio 0.35, 95% CI 0.17–0.70, across 4 studies and 829 infants) — and hypertensive disorders of pregnancy dropped by a similar margin (risk ratio 0.34, 95% CI 0.19–0.61). Caesarean section rates showed little to no difference between groups (risk ratio 0.91, 95% CI 0.77–1.07). Two findings are genuinely uncertain rather than reassuring: the risk of a large-for-gestational-age infant, measured in only one trial of 234 infants, had a risk ratio of 1.40 with a confidence interval spanning 0.65 to 3.02 — a result the Cochrane authors describe as consistent with both a real benefit and a real harm, which is a polite way of saying the single study was too small to tell. Neonatal hypoglycaemia results actively conflict across the literature: Matarrelli’s individual trial reported fewer hypoglycaemia episodes in the myo-inositol group, while the pooled analysis across four studies and 671 infants found the opposite direction of effect (risk ratio 3.07, 95% CI 0.90–10.52) — wide enough to include no effect at all, and rated very-low certainty. Neither result should be read as settled; both are exactly the kind of open question the review’s authors flagged for future, larger trials.

Can You Take Inositol While Trying to Conceive?

In an open, single-arm trial with no placebo comparison, 25 women with PCOS and oligo- or amenorrhea took 2 g of myo-inositol twice daily for six months, and 22 of them (88%) restored at least one spontaneous cycle, with 10 singleton pregnancies following — 9 confirmed by fetal heartbeat on ultrasound, 2 ending in spontaneous miscarriage. Because there was no comparison group, that 20%-of-pregnancies miscarriage figure cannot be read as either reassuring or concerning — there is nothing to measure it against, and it may simply reflect the background miscarriage rate in any small group of pregnancies. What the trial does support is the mechanism already established elsewhere: restoring ovulation is a plausible route to pregnancy for women whose cycles are insulin-resistance-driven, which is covered in full, including dose and timeline, in inositol for PCOS and when to take inositol. Whether cycles return at all is a different question from what happens once pregnancy is established, which is what the gestational-diabetes trials above actually measured — see can you get pregnant with PCOS for the wider conception-rate picture.

Can You Take Inositol While Breastfeeding?

Zero trials have tested myo-inositol supplementation in breastfeeding women, at any dose, for either maternal or infant outcomes — that is the honest, complete answer, and no amount of related data changes it. What does exist is context, not proof of safety: myo-inositol occurs naturally in human milk at a meaningfully higher concentration than in infant formula, with a 1975 analysis finding roughly 33 mg per 100 ml in colostrum, falling to about 15 mg per 100 ml in mature milk — more than double the concentration measured in cow’s milk at every stage. A 2023 study, funded in part by an infant-formula manufacturer, found that milk-derived myo-inositol promoted synapse formation in cultured human neurons and in the brains of supplemented mice. That study examined milk’s naturally occurring inositol and animal and cell models — it did not test what happens when a breastfeeding parent takes a myo-inositol supplement on top of their normal diet, and it was not designed to assess maternal supplementation safety, milk supply, or infant exposure at all. Put plainly: inositol is not a foreign compound in an infant’s diet, but that is not the same thing as a trial showing that supplementing it during lactation is safe, necessary, or without any effect on milk composition or supply. Nobody has run that trial. What the separate PCOS milk-supply research actually shows is a related but distinct question from inositol supplementation specifically.

Inositol is only one piece of a broader question — what NIH LactMed shows for others walks through berberine, NAC, and the rest of the common PCOS supplement list individually.

You may see the condition referred to as polyendocrine metabolic ovarian syndrome (PMOS), the name a 2026 global consensus of 56 organisations adopted for PCOS. None of the pregnancy or lactation evidence above changed with the rename — see PCOS is now PMOS for what did.

Who Should Not Take Inositol in Pregnancy or While Breastfeeding Without a Conversation First?

Four groups face a genuinely different risk-benefit picture than the trial averages above describe, and each is worth a specific conversation with a clinician rather than a general assumption either way.

• Anyone who has not been screened for, or does not have, an elevated gestational diabetes risk — the trials recruited specifically obese, overweight, or high-fasting-glucose participants, not every pregnant person; inositol has not been tested as a routine addition to an average-risk pregnancy.
• Anyone taking metformin or another glucose-lowering medicine during pregnancy — none of the trials above tested inositol combined with a diabetes medication in a pregnant population.
• Anyone who is breastfeeding, without exception, given that zero trials exist in that population. An absence of evidence of harm is not evidence of safety, and it should be treated as an open question rather than a green light.
• Anyone taking it for a reason unrelated to insulin resistance or gestational diabetes risk — no pregnancy trial has tested it for any other purpose.

Your Next Step

One conversation is worth having before starting or continuing inositol in pregnancy or while breastfeeding: bring the specifics above — which population was actually studied, the certainty rating on each finding, and the complete absence of breastfeeding data — to your prenatal or postpartum care provider, and let them weigh it against your individual risk factors rather than a generic recommendation. For what the ovulation and insulin trials found outside of pregnancy, see inositol for PCOS; for how it interacts with metformin, birth control, or thyroid medication, see inositol drug interactions; for the wider supplements picture, the supplements and medications section covers what else has trial evidence behind it.